Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01561-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Omar Janha und 8 weiteren Autor:innen. Beteiligte Einrichtung: Keltic Pharma Therapeutics Limited, Advanced Research Centre, University of Glasgow, Glasgow, United Kingdom. Hauptthemen laut MEDLINE: RNA Splicing, Antimalarials, Plasmodium falciparum, Protozoan Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Singapore, Wellcome Trust, Gates Family Foundation.
Abstract (Originalsprache)
Emerging resistance to front-line antimalarials means there is an urgent need to discover new drugs with novel mechanisms of action that remain effective across multiple stages of the parasite life cycle. Previously, we reported a malaria parasite protein kinase, Pf CLK3, as a target offering a cure, prophylaxis, and transmission blocking. The homology between Pf CLK3 and human kinases suggested that the mechanism of parasiticidal activity of Pf CLK3 inhibitors is disruption of RNA processing. Here, we use RNA sequencing to reveal that selective Pf CLK3 inhibition extensively affects RNA splicing with 2,039 splice-junctions across 1,125 genes mis-spliced in treated wild-type parasites compared to controls. The function of mis-spliced transcripts showed that the affected genes were involved in numerous essential parasite processes associated with multiple life cycle stages and revealed transcripts and introns particularly susceptible to inhibition. Our study supports the role of Pf CLK3 as an important regulator of spliceosome activity and establishes the distinct mechanism of parasiticidal activity of Pf CLK3 inhibitors from current front-line treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Keltic Pharma Therapeutics Limited, Advanced Research Centre, University of Glasgow, Glasgow, United Kingdom.
- School of Molecular Biosciences, Advanced Research Centre, University of Glasgow, Glasgow, United Kingdom.
- School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
- School of infection and Immunity, College of Medical, Veterinary and Life Science, University of Glasgow, Glasgow, United Kingdom.
- School of Chemistry Advanced Research Centre, University of Glasgow, Glasgow, United Kingdom.
ORCID-Profile: Omar Janha, Go Ka Diam, Dario Beraldi, Andrew G Jamieson, Andrew B Tobin, Katarzyna Modrzynska
Förderung
- Ministry of Education, Singapore
- Wellcome Trust
- Gates Family Foundation
- Gates Foundation
- Bill & Melinda Gates Foundation
- Royal Society
Zitieren
APA
Janha, O., Olaniyan, N., Diam, G. K., Sharma, S., Beraldi, D., Jamieson, A. G., Bozdech, Z., Tobin, A. B., & Modrzynska, K. (2026). Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01561-25
Vancouver
Janha O, Olaniyan N, Diam GK, Sharma S, Beraldi D, Jamieson AG, et al. Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01561-25
BibTeX
@article{Janha2026,
author = {Janha, Omar and Olaniyan, Niniola and Diam, Go Ka and Sharma, Saumya and Beraldi, Dario and Jamieson, Andrew G and Bozdech, Zbynek and Tobin, Andrew B and Modrzynska, Katarzyna},
title = {Inhibition of PfCLK3 interferes with malaria parasite RNA splicing and explains the mechanism of action of a new class of antimalarial candidates},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01561-25}
}
EUVIMED